Wire · opportunities
MapLight turns off preclinical tap to fund schizophrenia drug
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 22 August 2026 · Fusion42 review
MapLight Therapeutics is prioritising its phase 3-ready schizophrenia drug ML-007C-MA by pausing investment in preclinical and discovery-stage programs to fund its clinical development, supported by a $150 million private placement and existing cash reserves. The company aims to initiate a phase 3 schizophrenia trial with topline results expected in 2028 and is also advancing a phase 2 trial for Alzheimer’s disease psychosis.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You can expect capital and attention to shift heavily towards schizophrenia treatments with late-stage validation, as MapLight cuts early-stage programs. If you work in neuropsychiatric drug development, moving resources towards well-advanced candidates could capture investors now stepping back from discovery risk.
◆ Coverage
1 source · 14 Aug 2026
◆ Related on Wire
◆ Topics